CymaBay Therapeutics, Inc.
CBAYInactive ticker- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001042074
No open-market purchases or sales by CymaBay Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2026
- 13F value
- $0
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding CBAY, Q2 2026
No superinvestor reported holding CBAY at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by CymaBay Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2024 (view filing) | Feb 12 | 2 days | Dorling JanetDirector | SSale | −6.00K | $31.97 | −$191.8K | −100.0%0 after | 10b5-1 |
| Jan 22, 2024 (view filing) | Jan 19 | 3 days | McWherter CharlesPresident of R&D | SSale | −18.4K | $23.67 | −$435.7K | −55.1%15.0K after | 5 lots10b5-1 |
| Jan 16, 2024 (view filing) | Jan 16 | Same day | Menold DanielVice President, Finance | SSale | −10.0K | $23.58 | −$235.8K | −100.0%0 after | 10b5-1 |
| Jan 16, 2024 (view filing) | Jan 16 | Same day | Quinlan Paul TGeneral Counsel | SSale | −5.00K | $23.58 | −$117.9K | −100.0%0 after | |
| Jan 10, 2024 (view filing) | Jan 10 | Same day | Dorling JanetDirector | SSale | −6.00K | $23.86 | −$143.2K | −100.0%0 after | 10b5-1 |
| Dec 18, 2023 (view filing) | Dec 18 | Same day | McWherter CharlesPresident of R&D | SSale | −11.3K | $21.48 | −$243.5K | −43.0%15.0K after | 2 lots |
| Dec 15, 2023 (view filing) | Dec 15 | Same day | Menold DanielVice President, Finance | SSale | −21.5K | $21.99 | −$472.6K | −100.0%0 after | 2 lots10b5-1 |
| Dec 15, 2023 (view filing) | Dec 15 | Same day | Quinlan Paul TGeneral Counsel | SSale | −5.00K | $21.98 | −$109.9K | −100.0%0 after | |
| Dec 11, 2023 (view filing) | Dec 11 | Same day | Shah SujalChief Executive Officer | SSale | −64.9K | $20.00 | −$1.30M | −27.5%171.3K after | 2 lots10b5-1 |
| Dec 11, 2023 (view filing) | Dec 11 | Same day | Dorling JanetDirector | SSale | −6.00K | $20.07 | −$120.4K | −100.0%0 after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in CymaBay Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding CBAY in 13F filings for Q2 2026.